ENTX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Entera presents substantially enhanced anabolic effects of EB613, a first-in-class oral PTH(1-34) tablet, in postmenopausal women with osteoporosis at high fracture risk and outlines its Phase 3 trial design at ASBMR 2026Oct 13, 2026
- Entera Bio's Phase 2 osteoporosis data for EB613 was selected for plenary poster presentation at ASBMR 2026Aug 4, 2026
- Entera Bio received positive FDA feedback on its Phase 3 program for an oral osteoporosis treatmentJun 24, 2026
- Entera Bio received positive FDA feedback on its 12-month registrational Phase 3 study of EB613 for postmenopausal osteoporosisJun 22, 2026
- Entera Bio submitted a streamlined Phase 3 protocol to launch the registrational program for EB613 in postmenopausal osteoporosisMar 4, 2026